Skip to main content
ArticleOPEN ACCESS

Traffic lights for ruxolitinib

Blood
DOI: 10.1182/blood-2017-07-795880
6Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Newberry et al provide evidence that clonal evolution in patients with myelofibrosis (MF) who are receiving therapy with ruxolitinib correlates with discontinuation of treatment, mainly because of loss of response or progression, and also predicts shorter survival thereafter.1

Cite

CITATION STYLE

APA

Vannucchi, A. M., & Guglielmelli, P. (2017, August 31). Traffic lights for ruxolitinib. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-07-795880

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free